Semaglutide Recall: Harbin Jixianglong Biotech CP-030-20250711
Announced 2026-03-11 · FDA
FDA recall is for Semaglutide for Rx compounding use only from Harbin Jixianglong Biotech, Lot CP-030-20250711, Exp. Jul. 24, 2027. The recall is due to CGMP deviations, including failure to complete process validation and bacterial endotoxin method validation before distribution. The product was distributed nationwide in the United States.
| Brand | Harbin Jixianglong Biotech Co., Ltd. |
|---|---|
| Product | Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04 Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street, Limin Development Zone, Harbin, China |
| Reason | CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution |
| Severity | moderate |
| Units affected | N/A |
| Distribution | Nationwide within the United States |
| Agency | FDA |
| Recall / campaign no. | Lot #: CP-030-20250711, Exp. Date Jul. 24th, 2027 |
WHAT YOU SHOULD DO
- Do not use or distribute any Semaglutide from Lot CP-030-20250711.
- Quarantine the recalled product and remove it from circulation.
- Contact your healthcare provider or supplier for instructions on return, disposal, or replacement.
- Check the FDA recall notice for further details and guidance.
This is an automatically maintained record of an official recall notice. Details can change; always follow the official notice linked above. See all records in the Recall Database.